Nanordica Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Nanordica Medical is a private, clinical-stage medtech company spun out from Estonia's National Institute of Chemical Physics and Biophysics. The company has developed a novel wound dressing based on silk nanofibers and synergistic antibacterial nanoparticles (Premotiv® technology), designed to address the high unmet need in chronic wound care, particularly diabetic foot ulcers. It has achieved ISO 13485:2016 certification and is conducting a large-scale, multi-center clinical trial to validate its product's efficacy against the standard of care. The company raised €1.75M in 2024 to advance its clinical and commercial efforts.

Wound CareDiabetic Foot Ulcers

Technology Platform

Premotiv® nanotechnology platform utilizing a patented composition of natural silk nanofibers blended with synergistic antibacterial nanoparticles to prevent infection and promote wound healing simultaneously.

Opportunities

The global advanced wound care market, valued in the tens of billions, presents a massive opportunity, particularly in the high-cost, high-mortality segment of diabetic foot ulcers where current treatments are often inadequate.

Nanordica's technology, if proven superior in its large-scale trial, could capture significant market share by reducing amputations, mortality, and overall treatment costs.

The platform also allows for expansion into other chronic wound indications and potential oncology-supportive care.

Risk Factors

The company faces significant clinical risk, as its value depends entirely on positive results from its ongoing pivotal trial.

As a small, pre-revenue Estonian company, it also carries substantial commercialization and competition risks, needing to secure partnerships and compete against large, established wound care players.

Financial risk exists, as the €1.75M funding may be insufficient to reach commercialization, requiring further dilutive financing.

Competitive Landscape

Nanordica operates in the highly competitive advanced wound care market, competing against large medtech firms (e.g., Smith & Nephew, Mölnlycke, ConvaTec) that offer silver, foam, and other advanced dressings, as well as numerous startups with novel technologies. Its key differentiator is the Premotiv® nanotechnology's dual-action claim of simultaneous antibacterial and healing promotion, which it must prove in head-to-head trials against these established standards of care.

More companies in Europe - Other →